Agilent Technologies
About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Employees: 17,900
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
18% more call options, than puts
Call options by funds: $138M | Put options by funds: $116M
13% more funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 9 (+1) [Q1 2025]
2.65% less ownership
Funds ownership: 88.29% [Q4 2024] → 85.64% (-2.65%) [Q1 2025]
7% less funds holding
Funds holding: 1,060 [Q4 2024] → 981 (-79) [Q1 2025]
16% less capital invested
Capital invested by funds: $33.9B [Q4 2024] → $28.5B (-$5.34B) [Q1 2025]
18% less repeat investments, than reductions
Existing positions increased: 323 | Existing positions reduced: 393
34% less first-time investments, than exits
New positions opened: 92 | Existing positions closed: 139
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Jefferies Brandon Couillard 8% 1-year accuracy 2 / 25 met price target | 2%upside $116 | Hold Maintained | 21 Apr 2025 |
Wells Fargo Brandon Couillard 8% 1-year accuracy 2 / 25 met price target | 19%upside $135 | Overweight Maintained | 17 Apr 2025 |
Barclays Luke Sergott 29% 1-year accuracy 18 / 63 met price target | 1%upside $115 | Equal-Weight Maintained | 10 Apr 2025 |
Baird Catherine Schulte 11% 1-year accuracy 2 / 18 met price target | 40%upside $159 | Outperform Maintained | 27 Feb 2025 |
Financial journalist opinion
Based on 8 articles about A published over the past 30 days









